High-dose ranibizumab therapy for vascularized pigment epithelial detachment

Eye (Basingstoke)

Volumn 26, Issue 6, 2012, Pages 882-885

  Chan, C K ^a,b   Abraham, P ^c   Sarraf, D ^d,e  

^a Southern California Desert Retina Consultants   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

^c Black Hills Regional Eye Institute   (United States)

^d JULES STEIN EYE INSTITUTE   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

age related macular degeneration; anti vascular endothelial growth factor therapy; high dose ranibizumab

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CASE REPORT; DRUG MEGADOSE; FLUORESCENCE ANGIOGRAPHY; FUNDUS PHOTOGRAPHY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; INTRAOCULAR HEMORRHAGE; MALE; MEDICAL HISTORY; OPTICAL COHERENT TOMOGRAPHY; OPTICAL TOMOGRAPHY; PHOTOGRAPHY; RETINA DETACHMENT; RETINA EXUDATE; SUBRETINAL FLUID; VASCULARIZED PIGMENT EPITHELIAL DETACHMENT; VISUAL ACUITY;

EID: 84862498934     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2012.90     Document Type: Article

References (12)

1. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmol 2006; 113: 363-372.
2. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
3. Chan CK, Meyer CH, Gross JG, Abraham P, Nuthi ASD, Kokame GT et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007; 27: 541-551. (Pubitemid 46905143)
4. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
5. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al, for the ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1440.
6. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al, for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
7. Chuang EL, Bird AC. The pathogenesis of tears of the retinal pigment epithelium. Am J Ophthalmol 1988; 105: 285-290. (Pubitemid 18078112)
8. Pauleikoff D, Löffert D, Spital G, Radermacher M, Dohrmann J, Lommatzsch A et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 2002; 240: 533-538. (Pubitemid 36097080)
9. The Moorfields Macular Study Group. Retinal pigment epithelial detachments in the elderly: a controlled trial of argon laser photocoagulation. Br J Ophthalmol 1982; 66: 1-16.
10. Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 2007; 27: 445-450. (Pubitemid 46624284)
11. Antoszyk AN, Tuomi L, Chung CY, Singh A, for the FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): Year 2 results. Am J Ophthalmol 2008; 145: 862-874.
12. Boyer DS, Heier JS, Brown D, Francom SF, Ianchulev T, Rubio RG et al, for the SAILOR Study Group. A Phase IIIb Study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmol 2009; 116: 1731-1739.